Pentagon pulls its own testosterone screening guidance one day after publishing it

The Defense Department yanked mandatory testosterone deficiency screening rules for service members just 24 hours after posting them, a rapid reversal that raises questions about whether Defense Secretary Pete Hegseth's signature health initiative was ready for rollout.

The Defense Health Agency published "Clinical Guidance for Health and Human Performance Optimization" on its website on Wednesday, September 2. By Thursday, the page returned a notice saying the content had been "moved or been removed." A Pentagon official told The Hill the document was "temporarily rescinded to allow for updates," and that final clinical guidance would follow "shortly."

The one-day lifespan of a major clinical directive, one the Defense Secretary himself championed publicly in July, marks an unusual stumble for a Pentagon that has otherwise moved aggressively to reshape military culture and readiness under Hegseth's leadership.

Hegseth pitched the screening as a warfighter advantage

Hegseth announced the testosterone screening and treatment effort in July, framing it as central to keeping American troops at peak fighting condition. His argument was straightforward: the military spends heavily on weapons systems and platforms but underinvests in the health of the individual service member.

In his July remarks, Hegseth laid out the case directly:

"While we invest heavily in our weapon systems, platforms and gear, our most decisive tactical advantage will always be the individual warfighter. We have a sacred duty to maintain that advantage, which is why we must constantly look for new ways to optimize your performance, your resilience and your long-term health."

That rationale, treat the warfighter's body as seriously as the warfighter's rifle, resonated with a military community that has long complained about bureaucratic indifference to service members' long-term health outcomes. The screening program was designed to back up the rhetoric with action.

Under the now-rescinded guidance, male active-duty and reserve service members age 30 and older would have received testosterone blood tests as part of their annual health assessments. Men under 30 would only be tested if a health professional flagged a concern or the service member requested it. Those diagnosed with low testosterone would receive treatment, including testosterone replacement therapy, along with additional screenings. Female service members would have been asked about disrupted menstrual cycles that could signal hormonal dysregulation.

Hegseth's broader tenure at the Pentagon has not been without friction. Army Secretary Dan Driscoll is expected to step down after a months-long clash with the Defense Secretary, underscoring the intensity of Hegseth's push to reshape Pentagon operations.

Within 24 hours, the guidance vanished from the DHA website

The speed of the reversal is what stands out. Breitbart reported that the official DHA policy page returned a "PAGE NOT FOUND" error on Thursday, one day after going live. Reuters had also reported the rescission before The Hill confirmed it independently with a Pentagon official.

The Pentagon's explanation was thin. The unnamed official said only that the document needed "updates" and that interim guidance, a separate document titled "Interim Guidance on Testosterone Deficiency Screenings for Active Duty and Reserve Component Personnel", remained in effect. The official did not specify what updates were needed, whether the rescinded guidance contained errors, or how the interim and final versions differed.

The official did, however, reaffirm the Pentagon's broader commitment to the program:

"The Department remains committed to addressing hormone deficiencies, protecting the long-term health of its Service members and enabling peak operational performance."

That statement tracks with Hegseth's July framing. But commitment and execution are different things, and pulling a clinical directive within a single news cycle suggests the execution side needs work.

A University of Pennsylvania researcher questioned the premise

Even before the reversal, the scientific basis for mandatory population-wide screening drew skepticism. Derek Griffith, director of the program for research on men's health at the University of Pennsylvania, previously told The Hill that Hegseth's rationale was not backed by science. Griffith noted that only about 2 percent of the male population has low testosterone, a figure he said does not "suggest that this is a major problem" in the U.S. military.

Griffith did acknowledge that testosterone replacement therapy could help the small subset of men who genuinely have low levels. The dispute is not over whether low testosterone is real or treatable. It is over whether mandatory screening of every male service member over 30 is a proportionate response to a condition affecting a small fraction of the force.

That is a legitimate policy debate, and one the Pentagon apparently did not resolve before publishing its guidance. The fact that the document went live on a Wednesday and came down on a Thursday suggests the clinical details were not fully vetted, or that internal disagreements surfaced only after publication.

Newsmax reported that the guidance, which was set to take immediate effect, also included provisions for treating hormonal imbalances in women, including Hypoactive Sexual Desire Disorder, a detail that may have expanded the scope beyond what the Pentagon was prepared to defend publicly.

Unanswered questions pile up around the rollback

The Pentagon left several basic questions unaddressed. No official explained what specific "updates" prompted the rescission. No one clarified whether the interim guidance, which remains in effect, differs substantively from the pulled document. No one said how many active-duty and reserve members would have been affected by the screening requirement, or what treatments beyond TRT were contemplated.

The document reference number, DHA-IPM-26-007, now leads to a dead link on the DHA website. Just The News noted that officials promised a revised version would follow soon, but "shortly" and "soon" are not dates.

This is not the first time the administration has faced questions about follow-through on bold policy announcements. Sen. Kevin Cramer's blockade of Trump nominees over an unresolved Biden-era wetlands rule illustrates how even allies grow frustrated when the gap between announcement and implementation stretches too wide.

Hegseth's core instinct here is sound. The military has a genuine interest in the long-term health of its service members, and testosterone deficiency is a real medical condition with real effects on strength, endurance, and recovery. A Defense Secretary who wants to treat warfighters as the military's most valuable asset is saying something conservatives have argued for years.

But good policy requires good process. Publishing mandatory clinical guidance that has to be pulled within 24 hours does not inspire confidence that the Pentagon's health bureaucracy is operating at the standard Hegseth himself has set. The interim guidance remains in place, and the Pentagon says a final version is coming. When it arrives, it will need to be airtight, because the program's credibility now depends on getting the second attempt right.

Separately, FOIA records have revealed ongoing questions about communication practices within the administration, a reminder that process and transparency matter even when the underlying policy goals are defensible.

If the Pentagon wants to be taken seriously on warfighter health, it needs to publish guidance that can survive longer than a single news cycle.